Xu, Fujiang

Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies

Li, Y., Xu, C., Wang, B., Xu, F., Ma, F., Qu, Y., Jiang, D., Li, K., Feng, J., Tian, S., et al. (2022) · Nature Communications

Gastric Cancer Management and OutcomesAdvanced Proteomics Techniques and Applications

Cited by 80

Integrative proteogenomic characterization of early esophageal cancer

Li, L., Jiang, D., Zhang, Q., Liu, H., Xu, F., Guo, C., Qin, Z., Wang, H., Feng, J., Liu, Y., et al. (2023) · Nature Communications

Esophageal Cancer Research and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 67

Integrative proteogenomic characterization of early esophageal cancer

Li, L., Jiang, D., Zhang, Q., Liu, H., Qin, Z., Xu, F., Shen, D., Wang, H., Feng, J., Liu, Y., et al. (2021) · Nature Communications

Esophageal Cancer Research and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 67

Integrative proteogenomic characterization of early esophageal cancer

Li, L., Jiang, D., Zhang, Q., Liu, H., Qin, Z., Xu, F., Shen, D., Wang, H., Guo, C., Feng, J., et al. (2021) · Nature Communications

Esophageal Cancer Research and TreatmentAdvanced Proteomics Techniques and Applications

Cited by 67

The EZH2 selective inhibitor ZLD1039 attenuates UUO-induced renal fibrosis by suppressing YAP activation

Xia, Q., Xu, F., Zhang, L., Ding, W., Liu, J., Liu, J., Chen, M., Ou, S., Xu, Y., & Wen, L. (2025) · Molecular Biomedicine

Hippo pathway signaling and YAP/TAZChronic Kidney Disease and Diabetes

Cited by 7